Valeritas Holdings Inc

Valeritas — Investor Presentation (August 2018)

35 slides from Valeritas's investor presentation, Aug 9, 2018

  1. Slide 1: Valeritas Corporate Presentation August 2018

    Valeritas Corporate Presentation NASDAQ: VLRX August 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valerita

  3. Slide 3: Rapidly Ramping Revenue & Poised for Significant Value Creation

    Valeritas: Rapidly Ramping Revenue & Poised for Significant Value Creation Turnaround Significant Market Selling Model Validated, Attractive Financial Profile, Complete Opportunity Revenue Growth Accelerating Limited Additional Financing  Company and its  Global Type 2 diabetes  New high‐touch sa

  4. Slide 4: Type 2 Diabetes Overview: V-Go $1.6B U.S. Opportunity

    Type 2 Diabetes Overview: V‐Go® $1.6B U.S. Opportunity U.S. Diabetes Market Overview1 Key Type 2 Market Data Points ~23 million diagnosed people with diabetes . 5.6 million U.S. Type 2 patients on insulin 2 ~7 million (90%‐95% Type 2) Insulin Users . 80% of Type 2 patients on insulin are not achievi

  5. Slide 5: Current Insulin Delivery Standard of Care Highly Dissatisfying for Type 2 Insulin Users

    Current Insulin Delivery Standard of Care for Type 2 Highly Dissatisfying Type 2 Insulin Users Intentionally Skip and/or Current Insulin Delivery Standard of Care Forget to Take Injections1 Most Type 2 patients will not inject away from home2 “Drugs don’t work in people who don’t take them.” ‐C. Eve

  6. Slide 6: The V-Go Solution Designed for Patients with Type 2 Diabetes

    The V‐Go® Solution Designed for Patients with Type 2 Diabetes V‐Go’s Benefits Discreet, Low Profile Simple to Use Convenient Cost Neutral Better A1c Control* Self‐contained Sharps Container Pharmacy vs. DME * Company data, kff.org (11 published clinical papers and 48 presentations at National Confer

  7. Slide 7: V-Go Competition: Pens not Pumps

    V‐Go® Competition: Pens not Pumps Unique Needs of Type 2 Patients Creates Valeritas’ Opportunity & Differentiates it from Others TYPE 1 TYPE 2 Typical Patient Engaged / Advocate Embarrassment / Stigma Attitude Complex Device More Likely Less Likely Acceptable? (~30% of Type 1 are on pump therapy)1 W

  8. Slide 8: Strong Clinical Evidence

    Strong Clinical Evidence Demonstrated Statistically Published Significant Improvements in A1c1‐10 12 Clinical Papers V‐Go Patients Improved Quality of Life1 >1K Studied Lowered Total Daily Dose of Insulin Presentations at National (Prescribed / Administered)1‐10 56 Conferences KW8 Demonstrated Cost

  9. Slide 9: Slide KW8 Changed from to Kristy Willis, 8/4/2018

    Slide 8 KW8 Changed from 52 to 56 Kristy Willis, 8/4/2018

  10. Slide 10: V-Go: Improved A1c Control with Less Insulin

    V‐Go®: Improved A1c Control with Less Insulin A Prospective Study of 415 Patients Showed V‐Go Superiority vs. Standard Treatment Optimization (STO)1 Greater Improvement in A1c2 Less Insulin Used & More Cost Effective V‐Go STO n=169 n=246 29% Less Insulin with V‐Go (%) vs STO at 4 months A1c (54 vs 7

  11. Slide 11: New High-Touch Sales and Marketing Model

    New High‐Touch Sales and Marketing Model DIRECT SALES REPs ON‐LINE ADs EDUCATION PROMOTION INDIRECT REPs DEMO KIT KOLs DESIRE PRESCRIBE TARGETED PRINT ADs PATIENT PHYSICIAN CONFERENCES • Activate patients to seek and ask for V‐Go® • Target high insulin volume prescribers • Direct‐to‐Patient multi‐ch

  12. Slide 12: U.S. Direct Sales Footprint

    U.S. Direct Sales Footprint Significant Opportunity for Sustained Robust Growth via Disciplined Sales Force Expansion . ~50 Direct Reps . Disciplined addition of reps over time to achieve national coverage ©2018 Valeritas, Inc. 11

  13. Slide 13: Accelerating 20%+ Revenue Growth

    Accelerating 20%+ Revenue Growth $7,000 Sequential Quarterly Revenue Key Observations (in 000’s) (Q1 2016‐Q2 2018) . Q1 ‘16 revamped sales & marketing model $6,500 • Direct reps reduced from 64 to 28 in Jan ‘16 $6,000 • Focused high‐touch and higher‐service sales & marketing model adopted $5,500 . Q

  14. Slide 14: Our Goal: 15% Share in Addressable U.S. Markets

    13 Our Goal: 15% Share in Addressable U.S. Markets 15% Share of Type 2 Patients in U.S. (Already on Insulin but not at Goal) can Generate ~$1.6B Revenue Addressable U.S. Type 2 Target Share Annual U.S. Revenue Patient Population 2M Multiple 1 Daily Injections $700M With 15% Market Share 4.5M Insulin

  15. Slide 15: International Markets – Significant Market Opportunity

    International Markets –Significant Market Opportunity Global Diabetes Stats1 International Distribution Agreements . Currently 425 million suffer diabetes; expected to be . Recent international distribution 629 million by 2045 (~90% Type 2) agreements signed with premier regional distributors . Augu

  16. Slide 16: Robust Pipeline of New V-Go Products

    Robust Pipeline of New V‐Go Products V‐Go Line Extension Products Provide Path to the Broader Diabetes & Insulin Market V‐Go® V‐Go® SIMTM V‐Go® Prefill1 2 • Current product (Simple Insulin Management) Expected to: • Filled by patient by transferring insulin Expected to: • Eliminate filling step as i

  17. Slide 17: Strategy for Sustained Growth & Expansion

    Strategy for Sustained Growth & Expansion + Grow Our Share Expand Our Reach Leverage Pipeline • Expand # of targets per rep • V‐Go accessory • ~50 direct sales reps TM • Expand U.S. field presence V‐Go® SIM with blue tooth • Targeting ~1,200 prescribers (accounts) connectivity • Drive V‐Go® share in

  18. Slide 18: Stronger Device Margin Mitigates Future Capital Needed to Break-Even

    Stronger Device Margin Mitigates Future Capital Needed to Break‐Even Quarterly Revenue Level at Which 45% Gross Valeritas Projected Gross Margins * $70 ($ in million) Margin was Achieved 50% GM in Q4 2018 at $60 $61.1 $7M to $8M Revenue $50 $40 . High margin at low revenue $30 $27.0 . Profitability

  19. Slide 19: Financial Summary

    Financial Summary Financial Summary Quarterly Summary YTD Summary ($ in millions) 2Q18 2Q17 Change 2018 2017 Change Revenue $6.5 $4.8 +36% $12.6 $9.4 +34% Gross Profit $3.1 $1.8 +71.5% $6.0 $3.5 +69.4% Gross Margin 47.6% 37.7% +990 bp 47.6% 37.6% +1000 bp Net Loss $11.1 $12.0 ‐7.5% $22.7 $23.8 ‐4.6%

  20. Slide 20: Rapidly Ramping Revenue & Poised for Significant Value Creation

    Valeritas: Rapidly Ramping Revenue & Poised for Significant Value Creation Turnaround Significant Market Selling Model Validated, Attractive Financial Profile, Complete Opportunity Revenue Growth Accelerating Limited Additional Financing  Company and its  Global Type 2 diabetes  New high‐touch sa

  21. Slide 21: Appendix

    Valeritas Corporate Presentation Appendix NASDAQ: VLRX August 2018 ©2018 Valeritas, Inc.. 20

  22. Slide 22: 4.5M U.S. Type 2 Patients on Insulin are not Achieving A1c Goal

    4.5M U.S. Type 2 Patients on Insulin are not Achieving A1c Goal Despite Serious Health Consequences % of Type 2 Patients on Insulin NOT at Goal1 Impact of Improving A1c Control2 Every 1% improvement in A1c decreases diabetes related events in: AT A1c Goal NOT AT A1c Goal 20% 80% Deaths Heart Attacks

  23. Slide 23: Significant Market Opportunity for Valeritas in the U.S.

    Significant Market Opportunity for Valeritas in the U.S. U.S. Type 2 Diabetes Initial V‐Go® Target Market V‐Go® Potential Revenue 5.6M Patients with Type 2 2M Type 2 on Multiple Daily Injections Diabetes On Insulin1 With Current Sales Force 15% “IF” Market Share V‐G0® Revenue 2 2M on 15% $75 Million

  24. Slide 24: Robust Clinical Data

    Robust Clinical Data Validated Ability of V‐Go® to Deliver Clinically Relevant Reductions in A1c with Less Insulin V‐GoAL1 SIMPLE2 VALIDATE 13 EVIDENT4 IMPROVE5 JONES6 KAISER7 UMASS8 MOTIV9 ENABLE10 Baseline 9.9% 8.8% 9.6% 9.7% 9.8% 9.1% 9.8% 10.7% 8.7% 9.2% N=169 N=87 N=204 N=84 N= 103 N=69 N=60 N=

  25. Slide 25: Slide KW9 Reference was updated Kristy Willis, 8/4/2018

    Slide 23 KW9 Reference 1 was updated Kristy Willis, 8/4/2018

  26. Slide 26: Simple Titration Approach Significantly Lowered A1c

    Simple Titration Approach Significantly Lowered A1c Use of a weekly physician‐driven mealtime dosing titration approach with patients with Type 2 Diabetes uncontrolled on prior regimens A1c (%) Insulin Dose (Units) 8.7 144 A1c Goal Achievement Before V‐Go® On V‐Go < 7% 13% 47% 7.1* < 8% 60* 40% 87%

  27. Slide 27: Less Insulin Needed and Lower A1c vs. Multiple Injections

    Less Insulin Needed and Lower A1c vs. Multiple Injections Switching from Multiple Daily Injections to V‐Go® Results in Significant Reductions in Insulin and A1c VALIDATE evaluated patients switched to V‐Go when Glycemic Control was Suboptimal on Prior Regimens Prescribed On V‐Go 117 Patient 102 Repo

  28. Slide 28: Clinical Benefit Realized Broadly with V-Go

    KW10 Clinical Benefit Realized Broadly with V‐Go® Switching Patients from Insulin Injections to V‐Go Resulted in Improved A1c and Less Insulin Regardless of Baseline Insulin Regimen or Dose All Patients Switched to V‐Go Patients with High Dose MDI Switched to V‐Go (MDI Patients Prescribed between 90

  29. Slide 29: Slide KW10 New slide - needs full review Kristy Willis, /4/2018

    Slide 26 KW10 New slide - needs full review Kristy Willis, 8/4/2018

  30. Slide 30: Patients Who Utilize V-Go Like How it Fits into Their Lifestyle

    Patients Who Utilize V‐Go® Like How it Fits into Their Lifestyle >90% of Patients are satisfied with the ability of V‐Go to fit with their Lifestyle Extremely Satisfied = 39% Very Satisfied= 32% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=6% N=720 patients prescribed V‐Go dLife Survey 1Q 201

  31. Slide 31: Scalable Business Model to Drive Shareholder Value

    Scalable Business Model to Drive Shareholder Value Launch V‐Go® Prefill Expand Product Advance Sales Force Launch V‐Go Next in U.S. V‐Go SIMTM Gen / Line Collaborate (Int’l) Extensions Launch with h‐Patch Expand V‐Go® SIMTM Technology Increase Sales Force (U.S.) Begin to Share in U.S. prudently in C

  32. Slide 32: V-Go with V-Go SIM Technology

    KW11 V‐Go® with V‐Go SIMTM Technology Simple Insulin Management™ MANAGEMENT APPLICATIONS PATIENT PHYSICIAN INDUSTRY PAYERS V‐Go SIM sends data one‐way to a V‐Go SIM will enable Simple and Adherence, utilization and other Evidence of treatment Smart Device. SIM App provides Timely access to data that

  33. Slide 33: Slide KW11 Changes to title/some wording/some images - full review Kristy Willis, 8/4/2018

    Slide 29 KW11 Changes to title/some wording/some images - full review Kristy Willis, 8/4/2018

  34. Slide 34: V-Go: Easy to Use & High Quality Commercial Scale Manufacturing

    V‐Go®: Easy to Use & High Quality Commercial Scale Manufacturing V‐Go Device Overview V‐Go® EZ FILL Basal rate is 24 hour Basal rate begins spring‐driven with the push of a button Basal Chamber Basal rate Fluid flow Piston restrictor Insulin Needle Fluid Bolus Chamber • Simple filling does not requi

  35. Slide 35: Experienced and Proven Executive Management Team

    Experienced and Proven Executive Management Team Geoffrey Jenkins EVP Manufacturing Joseph Saldanha Operations, R&D Chief Business Officer John Timberlake President & CEO, Board Member Matt Nguyen Erick Lucera Chief Commercial Officer Chief Financial Officer ©2018 Valeritas, Inc. 31

Valeritas Holdings — Investor Presentation (August 2018) on 6ix